ストックスクリーナーアプリを入手
13.56
1.65%
0.22
前日終値:
$13.34
開ける：
$13.48
24時間の取引高:
182.79K
Relative Volume:
0.38
時価総額：
$936.26M
収益：
$26.98M
当期純損益:
$-180.66M
株価収益率:
-2.6433
EPS:
-5.13
ネットキャッシュフロー:
$-63.56M
1週間 パフォーマンス:
-8.44%
1か月 パフォーマンス:
-7.63%
6か月 パフォーマンス:
-39.27%
1年 パフォーマンス:
-23.61%
1日の値動き範囲:
$13.38
$13.90
1週間の範囲:
$13.20
$15.30
52週間の値動き範囲:
$12.17
$28.67
Bicycle Therapeutics Plc Adr Stock (BCYC) Company Profile
名前
Bicycle Therapeutics Plc Adr
セクター
電話
011441223261503
住所
BLOCKS A & B, PORTWAY BUILDING, CAMBRIDGE
BCYC を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BCYC
Bicycle Therapeutics Plc Adr
|
13.56 | 936.26M | 26.98M | -180.66M | -63.56M | -5.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Bicycle Therapeutics Plc Adr Stock (BCYC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-08 | 開始されました | Stephens | Equal-Weight |
| 2024-09-06 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-08-07 | ダウングレード | B. Riley Securities | Buy → Neutral |
| 2023-09-11 | アップグレード | B. Riley Securities | Neutral → Buy |
| 2022-08-31 | 開始されました | Cowen | Outperform |
| 2022-07-28 | 開始されました | Barclays | Overweight |
| 2022-07-06 | 再開されました | Canaccord Genuity | Buy |
| 2022-04-13 | ダウングレード | B. Riley Securities | Buy → Neutral |
| 2022-04-07 | 再開されました | Cantor Fitzgerald | Overweight |
| 2022-02-14 | 開始されました | Morgan Stanley | Equal-Weight |
| 2021-12-17 | 開始されました | SVB Leerink | Outperform |
| 2021-12-09 | 開始されました | Needham | Buy |
| 2021-09-30 | 開始されました | B. Riley Securities | Buy |
| 2021-04-20 | 開始されました | JMP Securities | Mkt Outperform |
| 2020-10-12 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-06-12 | 開始されました | Oppenheimer | Outperform |
| 2020-04-17 | 開始されました | H.C. Wainwright | Buy |
| 2019-11-14 | 開始されました | ROTH Capital | Buy |
| 2019-09-11 | アップグレード | Goldman | Neutral → Buy |
| 2019-06-17 | 開始されました | Canaccord Genuity | Buy |
| 2019-06-17 | 開始されました | Goldman | Neutral |
| 2019-06-17 | 開始されました | Jefferies | Buy |
| 2019-06-17 | 開始されました | Piper Jaffray | Overweight |
すべてを表示
Bicycle Therapeutics Plc Adr (BCYC) 最新ニュース
Bicycle Therapeutics' SWOT analysis: platform potential drives stock outlook - Investing.com India
Bicycle Therapeutics reports promising cancer drug trial results - Investing.com India
Bicycle therapeutics CDO Santiago Arroyo sells shares worth $69,646 - Investing.com India
Bicycle Therapeutics CFO Alethia Young sells shares totaling $19,655 - Investing.com
Bicycle Therapeutics exec sells $30k in shares - Investing.com
Bicycle Therapeutics CAO Travis Thompson sells $67,292 in shares By Investing.com - Investing.com South Africa
Bicycle Therapeutics CTO sells shares worth $60,119 By Investing.com - Investing.com South Africa
Bicycle Therapeutics CAO Travis Thompson sells $67,292 in shares - Investing.com
Bicycle Therapeutics CEO Lee sells shares worth $172,952 By Investing.com - Investing.com South Africa
Bicycle Therapeutics CEO Lee sells shares worth $172,952 - Investing.com India
Bicycle Therapeutics' SWOT analysis: stock outlook amid clinical trials and cash strength - Investing.com India
Bicycle Therapeutics' SWOT analysis: stock's potential rides on clinical data By Investing.com - Investing.com South Africa
Bicycle Therapeutics' SWOT analysis: stock's potential rides on clinical data - Investing.com
FDA Accepts GSK's Filing for Expanded Use of Nucala in COPD - Yahoo Finance
ALEC Stock Tanks as Alzheimer's Drug Fails in Mid-Stage Study - Yahoo Finance
Pharmacovigilance and Drug Safety Software Market Size to Reach USD 371.88 Million by 2032, Growing at a 6.76% CAGR – SNS Insider - Yahoo Finance
SAGE's Dalzanemdor Fails to Meet Goal in Huntington's Disease Study - Yahoo Finance
ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap - Yahoo Finance
Merck Inks $3.3B Licensing Deal With Chinese Biotech for Cancer Therapy - Yahoo Finance
Bicycle Therapeutics' SWOT analysis: innovative platform fuels stock's potential - Investing.com India
Bicycle Therapeutics' chief accounting officer sells shares worth $157,113 - Investing.com
Bicycle Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results - Yahoo Finance
Bicycle Therapeutics' SWOT analysis: stock's potential rides on innovative platform - Investing.com India
Bicycle Therapeutics retains stock target and Buy rating on promising data - Investing.com
Bicycle Therapeutics spotlights cancer treatment targets - Investing.com
Novartis Gets CHMP Recommendation for Kisqali in Broader Population - Yahoo Finance
Bicycle Therapeutics (BCYC) Soars 5.7%: Is Further Upside Left in the Stock? - MSN
A company insider recently sold 3,212 shares of Bicycle Therapeutics Plc ADR [BCYC]. Should You also Consider to Sale? – Knox Daily - Knox Daily
BCYC’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - The InvestChronicle
Keeping an Eye on Bicycle Therapeutics Plc ADR (BCYC) After Insider Trading Activity - Knox Daily
Bicycle Therapeutics Plc ADR (BCYC)’s stock price range in the last year - US Post News
Bicycle therapeutics executive sells shares worth over $21k - Investing.com India
Bicycle therapeutics executive sells shares to cover tax obligations - Investing.com India
Bicycle therapeutics COO sells shares worth over $21k - Investing.com India
Bicycle therapeutics CEO sells shares worth over $71k - Investing.com
Bicycle therapeutics CTO sells shares worth over $21k - Investing.com
Bicycle therapeutics executive sells shares worth over $5,000 - Investing.com
CHIEF PROD & SUPPLY CHAIN OFF Hannay Michael Charles Ferguso sale 246 shares of Bicycle Therapeutics Plc ADR [BCYC] – Knox Daily - Knox Daily
Bicycle Therapeutics Plc ADR (BCYC)’s stock chart: A technical perspective - US Post News
Market Update: Bicycle Therapeutics Plc ADR (BCYC) Sees Negative Movement, Closing at 22.56 - The Dwinnex
Bayer Reports Positive Safety Data on Parkinson's Disease Drug - Yahoo Finance
Wall Street SWOT: Bicycle Therapeutics stock rides high on cancer drug promise - Investing.com
A company insider recently sold 246 shares of Bicycle Therapeutics Plc ADR [BCYC]. Should You Sale? - Knox Daily
Nothing is Better Than Bicycle Therapeutics Plc ADR (BCYC) stock at the moment - SETE News
RBC Capital Mkts initates Bicycle Therapeutics Plc ADR (BCYC) stock to an Outperform - Knox Daily
Metric Analysis: Bicycle Therapeutics Plc ADR (BCYC)’s Key Ratios in the Limelight - The Dwinnex
Bicycle Therapeutics Plc ADR: A Year of Highs, Lows, and Market Resilience - The InvestChronicle
Are Bicycle Therapeutics Plc ADR (BCYC) shares a good deal now? - US Post News
Hain Celestial Group Inc [HAIN] Investment Guide: What You Need to Know - Knox Daily
Bicycle Therapeutics stock maintains Buy rating post-ESMO data By Investing.com - Investing.com UK
Bicycle Therapeutics Plc Adr (BCYC) 財務データ
収益
当期純利益
現金流量
EPS
4.81%
大文字化:
|
ボリューム (24 時間):